Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TLSA Tiziana Life Sciences PLC

Post-Mkt 12-11 18:50:09 EST

1.72

-0.08

-4.44%

盘后1.73

+0.01+0.58%

17:38 EST

High1.82	Low1.70	Vol145.76K
Open1.76	D1 Closing1.80	Amplitude6.67%
Mkt Cap204.68M	Tradable Cap118.30M	Total Shares119.00M
T/O257.41K	T/O Rate0.21%	Tradable Shares68.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TLSA","market":"US","secType":"STK","nameCN":"Tiziana Life Sciences PLC","latestPrice":1.72,"timestamp":1765486800000,"preClose":1.8,"halted":0,"volume":145761,"hourTrading":{"tag":"盘后","latestPrice":1.73,"preClose":1.72,"latestTime":"17:38 EST","volume":7979,"amount":13599.8392639,"timestamp":1765492721443},"delay":0,"floatShares":68779500,"shares":119000000,"eps":-0.1131,"marketStatus":"Post-Mkt","change":-0.08,"latestTime":"12-11 18:50:09 EST","open":1.76,"high":1.82,"low":1.7,"amount":257412.6433032,"amplitude":0.066667,"askPrice":1.74,"askSize":671,"bidPrice":1.68,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-0.1131,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1765501200000},"marketStatusCode":4,"adr":0,"adrRate":2,"listingDate":1542690000000,"exchange":"NASDAQ","adjPreClose":1.8,"preHourTrading":{"tag":"盘前","latestPrice":1.75,"preClose":1.8,"latestTime":"09:25 EST","volume":809,"amount":1445.699989,"timestamp":1765463113272},"postHourTrading":{"tag":"盘后","latestPrice":1.73,"preClose":1.72,"latestTime":"17:38 EST","volume":7979,"amount":13599.8392639,"timestamp":1765492721443},"volumeRatio":0.666941,"impliedVol":1.0079,"impliedVolPercentile":0.448},"requestUrl":"/m/hq/s/TLSA","defaultTab":"news","newsList":[{"id":"2588030542","title":"Tiziana Life Sciences to Spin Out IL-6 Asset into Separate Public Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2588030542","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588030542?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:00","pubTimestamp":1764676831,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. has announced plans to spin out its fully human anti-IL-6 receptor monoclonal antibody, TZLS-501, and related assets into a separate publicly traded company. The move aims to enhance strategic focus and unlock value for shareholders, who will receive shares in the new entity via a distribution in specie. The spinout, which will center on the IL-6 market, is subject to shareholder approval and meeting listing requirements. The decision follows increased industry interest in IL-6 pathway therapeutics, highlighted by Novartis' recent $1.4 billion acquisition of Tourmaline Bio.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL7PC3yD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210149790.SGD","LU2210150020.SGD","TLSA","BK4139","NDAQ","IE00BKPKM429.USD","BK4112","BK4588","BK4585","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2095319765.USD"],"gpt_icon":0},{"id":"2588030878","title":"Tiziana Life Sciences Plans to Spinout Il-6 Asset Into Separate Listed Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2588030878","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588030878?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:00","pubTimestamp":1764676812,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80KM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TLSA"],"gpt_icon":0},{"id":"2588003089","title":"Tiziana Life Sciences Ltd - Co Shareholders to Receive Shares in New Tzls-501 Entity","url":"https://stock-news.laohu8.com/highlight/detail?id=2588003089","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588003089?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:00","pubTimestamp":1764676812,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80KM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2586464475","title":"Tiziana Life Sciences Wins ALS Association Grant for Phase 2 Nasal Foralumab Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2586464475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586464475?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:30","pubTimestamp":1764077409,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. has received a competitive grant from the ALS Association to support its Phase 2 clinical trial of intranasal foralumab for patients with amyotrophic lateral sclerosis . The grant was awarded following a rigorous peer review process. The trial has also been accepted into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS at Mass General Brigham and will be conducted at multiple U.S. centers within the NEALS Consortium. The funding is specifically for Tiziana Life Sciences Ltd.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire  on November 25, 2025, and is solely responsible for the informa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL32l4r3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4588","LU2210150020.SGD","TLSA","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","NDAQ","BK4585","BK4139"],"gpt_icon":0},{"id":"2586103475","title":"Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted Into Healey ALS Mymatch Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2586103475","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586103475?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:30","pubTimestamp":1764077400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nTUA2YJ985:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TLSA"],"gpt_icon":0},{"id":"2583750594","title":"Tiziana Life Sciences Ltd. Announces Date for Upcoming Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2583750594","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583750594?lang=en_us&edition=fundamental","pubTime":"2025-11-13 23:46","pubTimestamp":1763048785,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. has announced that it will hold its Annual General Meeting remotely on December 16, 2025. During the meeting, shareholders will vote on several resolutions, including the re-election of John Brancaccio as a Class II director and Willy Simon as a Class III director, each to serve until the annual general meeting in 2028. Other items on the agenda include receiving the auditor's report and financial statements for the year ended December 31, 2024, and the re-appointment of PKF LittleJohn LLP as auditors, with authorization for the directors to fix the auditors' remuneration. Any other business that may properly come before the meeting or its adjournment will also be considered.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDLc3lV5h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2583935855","title":"Tiziana Life Sciences to Present at Jefferies London Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2583935855","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583935855?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:30","pubTimestamp":1763040619,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. will present at the Jefferies London Healthcare Conference on November 19, 2025. The company's senior leadership will provide a corporate overview and share updates on its innovative pipeline, including its lead candidate foralumab, an intranasal anti-CD3 monoclonal antibody in clinical development for neurodegenerative diseases such as non-active secondary progressive multiple sclerosis, Alzheimer's disease, multiple system atrophy, and amyotrophic lateral sclerosis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire  on November 13, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDLbc30JH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","NDAQ","LU2095319765.USD","BK4139","LU0314104364.USD","IE00B64PRP62.GBP","BK4112","IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD","IE00BKPKM429.USD","TLSA","BK4585","BK4588"],"gpt_icon":0},{"id":"2580739315","title":"BRIEF-Aquestive Therapeutics Announces Leadership Expansion To Support Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2580739315","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580739315?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:32","pubTimestamp":1762259544,"startTime":"0","endTime":"0","summary":"BRIEF-Aquestive Therapeutics Announces Leadership Expansion To Support GrowthNov 4 (Reuters) - Aquestive Therapeutics Inc AQST.O:AQUESTIVE THERAPEUTICS ANNOUNCES LEADERSHIP EXPANSION TO SUPPORT GROWTHSource text: ID:nGNX71615SFurther company coverage: AQST.O ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA8J49N6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TLSA","AQST","BK4139"],"gpt_icon":0},{"id":"2580733166","title":"Aquestive Therapeutics Announces Leadership Expansion to Support Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2580733166","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580733166?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:00","pubTimestamp":1762257605,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA8J49N6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","AQST","TLSA"],"gpt_icon":0},{"id":"2572337626","title":"Tiziana Life Sciences Reports $5.3 Million Loss for First Half of 2025, Cash Balance Rises to $7.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2572337626","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572337626?lang=en_us&edition=fundamental","pubTime":"2025-10-04 04:31","pubTimestamp":1759523489,"startTime":"0","endTime":"0","summary":"For the six months ended June 30, 2025, Tiziana Life Sciences Ltd. reported a total comprehensive loss of $5.3 million, compared to a loss of $4.7 million for the same period in 2024. As of June 30, 2025, cash was $7.3 million, compared to $3.7 million as of December 31, 2024. Other receivables were $5.3 million as of June 30, 2025, compared to $3.8 million as of December 31, 2024. After the reporting period, an additional $2 million was raised from the sale of investment shares and ATM issuances.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL5pt6gh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLSA"],"gpt_icon":0},{"id":"2570090236","title":"Tiziana Life Sciences to Advance Anti-Inflammation Therapy Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2570090236","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570090236?lang=en_us&edition=fundamental","pubTime":"2025-09-25 21:00","pubTimestamp":1758805242,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences  said Thursday that it will advance its second asset, TZLS-501, a monoclonal antibody targeting inflammation, lung damage, and chronic fibrosis in multiple diseases, including rheumatoid arthritis, acute respiratory distress syndrome, lupus, and various cancers.Tiziana said it will pursue non-dilutive funding strategies for the development of TZLS-501 while continuing to advance intranasal foralumab as its lead program.The company said it sees the potential to develop TZLS-501 as either a monotherapy or in combination with foralumab as well as with other anti-inflammatory and anti-infective agents.Tiziana said its pursuit of the development of TZLS-501 will not divert resources or focus from ongoing clinical trials with foralumab.Shares of Tiziana were down 1% in recent premarket activity Thursday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2570972170","title":"Tiziana Life Sciences to advance TZLS-501 monoclonal antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2570972170","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570972170?lang=en_us&edition=fundamental","pubTime":"2025-09-25 20:35","pubTimestamp":1758803722,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences (TLSA) will advance its second asset, a fully human anti-IL-6 receptor monoclonal antibody, TZLS-501. Tiziana will pursue non...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tiziana-life-sciences-to-advance-tzls-501-monoclonal-antibody-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tiziana-life-sciences-to-advance-tzls-501-monoclonal-antibody-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2570690097","title":"Tiziana Life Sciences Ltd - Will Pursue Non-Dilutive Funding Strategies for Development of Tzls-501","url":"https://stock-news.laohu8.com/highlight/detail?id=2570690097","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570690097?lang=en_us&edition=fundamental","pubTime":"2025-09-25 20:31","pubTimestamp":1758803487,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nFWN3VC11B:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2570097697","title":"Tiziana to Advance Tzls-501 - Its Fully Human Il-6R Monoclonal Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2570097697","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570097697?lang=en_us&edition=fundamental","pubTime":"2025-09-25 20:31","pubTimestamp":1758803487,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nFWN3VC11B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TLSA"],"gpt_icon":0},{"id":"2569019467","title":"Tiziana Life announces poster presentation on intranasal foralumab trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2569019467","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569019467?lang=en_us&edition=fundamental","pubTime":"2025-09-24 20:40","pubTimestamp":1758717639,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences (TLSA) announced that it will present a scientific poster at the 41st Congress of the European Committee for Treatment and Re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tiziana-life-announces-poster-presentation-on-intranasal-foralumab-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tiziana-life-announces-poster-presentation-on-intranasal-foralumab-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2569170139","title":"Tiziana Life Sciences Announces Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis at ECTRIMS 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2569170139","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569170139?lang=en_us&edition=fundamental","pubTime":"2025-09-24 20:31","pubTimestamp":1758717060,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Announces Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis at ECTRIMS 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 24, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nNDLnj1pm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2569701850","title":"Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41St Ectrims Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2569701850","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569701850?lang=en_us&edition=fundamental","pubTime":"2025-09-24 20:30","pubTimestamp":1758717000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nTUA8P74BF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"gpt_icon":0},{"id":"2569475156","title":"Tiziana Life Sciences Leads A Trio Of Promising Penny Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2569475156","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569475156?lang=en_us&edition=fundamental","pubTime":"2025-09-23 01:05","pubTimestamp":1758560714,"startTime":"0","endTime":"0","summary":"As the U.S. stock market continues its upward trajectory, with the S&P 500 and Nasdaq reaching new all-time highs, investors are on the lookout for opportunities that align with current economic trends. Penny stocks, a term that may seem outdated but still relevant, represent smaller or less-established companies that could offer significant value under these conditions. By focusing on those with strong financial health and potential for growth, investors can uncover promising opportunities...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tlsa/tiziana-life-sciences/news/tiziana-life-sciences-leads-a-trio-of-promising-penny-stocks","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tlsa/tiziana-life-sciences/news/tiziana-life-sciences-leads-a-trio-of-promising-penny-stocks","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CIB","BK4173","BK4157","BK4141","TLSA","BK4509","SMH","BK4585","BABB","PSHG","TBTC","BK4551","BK4139","BK4554","BK4209","BK4021","BK4180","BK4207","WDH","BK4539","BK4078","BK4023","PBYI","DDL","BK4150","VUZI","SOXX","BK4179","BK4588","BK4113","KLNG","VLN","LCUT","MAPS"],"gpt_icon":1},{"id":"2567611972","title":"Tiziana Life Sciences Secures Department of Defense Grant to Advance Intranasal Anti-CD3 Therapy for Spinal Cord Injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2567611972","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567611972?lang=en_us&edition=fundamental","pubTime":"2025-09-15 20:01","pubTimestamp":1757937695,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Ltd. has been awarded a grant by the U.S. Department of Defense to advance its intranasal anti-CD3 therapy for traumatic spinal cord injury. This funding will support a three-year study focusing on the acute phase of spinal cord injury, targeting patients immediately after trauma. Additionally, a two-year Stepping Strong Breakthrough Award will extend research into the chronic phase, addressing long-term neurological deficits. The initiative marks a significant step in exploring the therapeutic potential of Tiziana's intranasal anti-CD3 platform beyond its current applications in autoimmune and neuroinflammatory diseases. Collaborating with researchers at Brigham and Women's Hospital, Tiziana aims to develop a non-invasive treatment that could improve quality of life for nearly 300,000 Americans living with permanent spinal cord disabilities.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL68tN0m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLSA"],"gpt_icon":0},{"id":"2567511920","title":"Tiziana Life Sciences Ltd: Dod Award Will Support a Three-Year Study of Intranasal Anti-Cd3 in Acute Phase of Sci","url":"https://stock-news.laohu8.com/highlight/detail?id=2567511920","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567511920?lang=en_us&edition=fundamental","pubTime":"2025-09-15 20:01","pubTimestamp":1757937686,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nFWN3V2052:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tizianalifesciences.com","stockEarnings":[{"period":"1week","weight":0.0651},{"period":"1month","weight":0.0286},{"period":"3month","weight":0.0056},{"period":"6month","weight":0.1613},{"period":"1year","weight":0.8309},{"period":"ytd","weight":1.5855}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-  receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":0.069015},{"month":2,"riseRate":0.142857,"avgChangeRate":0.005731},{"month":3,"riseRate":0.428571,"avgChangeRate":0.177199},{"month":4,"riseRate":0.571429,"avgChangeRate":0.151459},{"month":5,"riseRate":0.428571,"avgChangeRate":0.199364},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.000341},{"month":7,"riseRate":0.428571,"avgChangeRate":0.326851},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.143149},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.016089},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.076885},{"month":11,"riseRate":0,"avgChangeRate":-0.127748},{"month":12,"riseRate":0,"avgChangeRate":-0.11113}],"exchange":"NASDAQ","name":"Tiziana Life Sciences PLC","nameEN":"Tiziana Life Sciences PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tiziana Life Sciences PLC(TLSA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tiziana Life Sciences PLC,TLSA,Tiziana Life Sciences PLC股票,Tiziana Life Sciences PLC股票老虎,Tiziana Life Sciences PLC股票老虎国际,Tiziana Life Sciences PLC行情,Tiziana Life Sciences PLC股票行情,Tiziana Life Sciences PLC股价,Tiziana Life Sciences PLC股市,Tiziana Life Sciences PLC股票价格,Tiziana Life Sciences PLC股票交易,Tiziana Life Sciences PLC股票购买,Tiziana Life Sciences PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tiziana Life Sciences PLC(TLSA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction